Hussein A. Tawbi
A5000768609- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Immune cells in cancer
- Brain Metastases and Treatment
- Cutaneous Melanoma Detection and Management
- Gut microbiota and health
- Glioma Diagnosis and Treatment
- Nanoplatforms for cancer theranostics
- Antimicrobial Peptides and Activities
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Tryptophan and brain disorders
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Computational Drug Discovery Methods
- Immune Cell Function and Interaction
- Histone Deacetylase Inhibitors Research
- Lung Cancer Research Studies
- PI3K/AKT/mTOR signaling in cancer
- Radiomics and Machine Learning in Medical Imaging
- Hedgehog Signaling Pathway Studies
- Cancer-related gene regulation
The University of Texas MD Anderson Cancer Center
2016-2025
Research Network (United States)
2025
Fate Therapeutics (United States)
2024
Mersana Therapeutics (United States)
2024
Sanofi (France)
2024
Boehringer Ingelheim (India)
2024
Dragonfly Therapeutics (United States)
2024
Novartis (Germany)
2024
Roche (Switzerland)
2018-2024
Bristol-Myers Squibb (Germany)
2018-2024
Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined oral and of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes1,2. The clinical presentation patients different subtypes is often atypical, and responses to therapies such as immune checkpoint blockade vary widely3,4. To explain this variability, here we study gene expression profiles in 608 tumours across soft-tissue sarcoma. We establish an immune-based classification on the basis composition tumour microenvironment identify five distinct...
Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies nivolumab combined ipilimumab melanoma have excluded untreated brain metastases. We evaluated the efficacy safety plus who had
Immune checkpoint blockade produces clinical benefit in many patients. However, better biomarkers of response are still needed, and mechanisms resistance remain incompletely understood. To address this, we recently studied a cohort melanoma patients treated with sequential against cytotoxic T lymphocyte antigen-4 (CTLA-4) followed by programmed death receptor-1 (PD-1) identified immune markers resistance. Building on these studies, performed deep molecular profiling including cell receptor...
This multicenter study, to our knowledge, is the first phase III trial compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy an anthracycline and at least one additional systemic regimen.Patients were randomly assigned a 2:1 ratio receive intravenously every 3 weeks. The primary end point was overall survival (OS), secondary points disease control-progression-free (PFS), time progression, objective response rate, duration of...
Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, nivolumab, PD-1-blocking has been shown be safe have antitumor activity in patients with previously treated melanoma, but the safety untreated melanoma need investigation.In this phase 2-3, global, double-blind, randomized trial, we evaluated relatlimab nivolumab as fixed-dose compared...
Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer, but effect of diet and supplements on this interaction is not well studied. We assessed fecal microbiota profiles, dietary habits, commercially available probiotic supplement use melanoma patients performed parallel preclinical studies. Higher fiber was associated with significantly improved progression-free survival 128 ICB, most pronounced benefit observed sufficient intake no use. Findings were...
Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal (RCC). In an increase overall survival has been with anti-CTLA-4 PD-1 inhibition. However, a plethora of immune-mediated adverse events reported these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors single cases variable presentation, myocarditis pericarditis. Among six clinical centers...
We evaluated neoadjuvant ipilimumab in patients with surgically operable regionally advanced melanoma order to define markers of activity the blood and tumor as assessed at baseline (before ipilimumab) early on-treatment. Patients were treated (10 mg/kg intravenously every 3 weeks ×2 doses) bracketing surgery. Tumor biospecimens obtained Flow cytometry immunohistochemistry for select biomarkers performed. Thirty five enrolled; IIIB (3; N2b), IIIC (32; N2c, N3), IV (2). Worst toxicities...
Abstract There is a critical need to improve our understanding of the pathogenesis melanoma brain metastases (MBM). Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases; tumors with sufficient tissue also underwent whole-exome sequencing, T-cell receptor IHC. demonstrated heterogeneity immune infiltrates that correlated prior radiation post-craniotomy survival. Comparison identified significant immunosuppression enrichment oxidative...
Abstract Relatlimab and nivolumab combination immunotherapy improves progression-free survival over monotherapy in patients with unresectable advanced melanoma 1 . We investigated this regimen resectable clinical stage III or oligometastatic IV (NCT02519322). Patients received two neoadjuvant doses (nivolumab 480 mg relatlimab 160 intravenously every 4 weeks) followed by surgery, then ten of adjuvant therapy. The primary end point was pathologic complete response (pCR) rate 2 resulted 57%...
As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly maximize patient benefit. New agents commonly evaluated for activity in patients who had previously received programmed death receptor 1 (PD-1)/programmed death-ligand (PD-L1) inhibitor as standard care or an investigational study. However, because kinetics patterns response PD-1/PD-L1 blockade, lack consistency clinical definitions resistance therapy,...
Significance A substantial portion of cancer patients treated by immune checkpoint (IC) therapy develop immune-related adverse events (irAEs), which result in significant morbidity and mortality. We sought to understand the mechanisms these irAEs identify biomarkers predict maximize clinical benefits IC therapy. screened plasma samples from who developed therapy-induced hypophysitis or pneumonitis against a cDNA expression library brain lungs directly identified autoimmune antibodies...
<h3>Background</h3> Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early addition of TNF-α such as infliximab (IFX) expedite symptom resolution shorten CS duration. Thus, we conducted first retrospective study, to our knowledge, evaluating in patients with irEC treated...